Effective November 1,2015, the CADAP Program will be requiring income and residency verification for first time and renewal applications. Please follow the links below to view the requirements.
Important Product Announcement
Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., has announced that for business reasons, Merck is voluntarily discontinuing the manufacture and distribution of PEGINTRON vials in the United States, effective February 1,2016.
Merck is also voluntarily discontinuing the manufacture and distribution of REBETOL in the United States, effective February 1, 2016.
Based on current inventory levels and expected demand, Merck anticipates that wholesaler inventory will be exhausted in or around February 2016, though inventory of certain images may be exhausted as early as the end of the fourth quarter of 2015.
If you are a CADAP client and this matter should affect you, please contact your medical provider.
Connecticut Insurance Premium Assistance (CIPA) Program
The CIPA Program is a health insurance assistance program funded through the Connecticut AIDS Drug Assistance Program (CADAP) for individuals living with HIV/AIDS who are CADAP-eligible. CIPA will help pay health insurance premiums for eligible individuals who have coverage through a CIPA-approved health insurance policy. CIPA is collaboration between the Department of Public Health and the Department of Social Services. www.mycipa.com
Content Last Modified on 1/17/2017 2:50:33 PM